Binding of aberrant glycoproteins recognizable by Helix pomatia agglutinin in adrenal cancers
Autor: | Gregory P. Sadler, Susan A. Brooks, M. E. Nga, Kee Yuan Ngiam, G. S. T. Soon, W. B. Tan, Radu Mihai, Rajeev Parameswaran |
---|---|
Rok vydání: | 2018 |
Předmět: |
chemistry.chemical_classification
endocrine system 030213 general clinical medicine Pathology medicine.medical_specialty Glycosylation business.industry Cancer General Medicine medicine.disease medicine.disease_cause Metastasis 03 medical and health sciences Cushing syndrome chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Cancer cell Medicine Immunohistochemistry business Glycoprotein Carcinogenesis |
Zdroj: | BJS Open. 2:353-359 |
ISSN: | 2474-9842 |
Popis: | Background Aberrant glycosylation is a hallmark of cancer cells and plays an important role in oncogenesis and cancer progression including metastasis. This study aimed to assess alteration in cellular glycosylation, detected by lectin Helix pomatia agglutinin (HPA) binding, in adrenal cancers and to determine whether such altered glycosylation has prognostic significance. Methods HPA binding lectin histochemistry was performed on archival paraffin wax-embedded specimens of adrenocortical cancers excised from patients attending two tertiary referral centres. Benign tumours were used as controls. Demographic, histological and survival data were collected and compared between patients with HPA-positive and HPA-negative tumours. Results Thirty-two patients were treated for adrenal cancer between 2000 and 2016; their median age was 49 (range 23-79) years. Fifteen patients had functioning tumours (14 adrenal Cushing's tumours and 1 Conn's tumour). Mean(s.d.) tumour size was 127·71(49·70) mm. None of 10 control tumours expressed HPA-binding glycoproteins. Invasion was associated with HPA-binding glycoproteins (P = 0·018). Local recurrence or metastatic disease did not significantly differ between HPA-positive and HPA-negative adrenocortical cancers. Overall survival was significantly longer in patients with HPA-negative tumours (median survival not reached versus 22 months in patients with HPA-positive tumours; P = 0·002). Conclusion Altered cellular glycosylation detected by lectin HPA is associated with poor survival in patients with adrenocortical cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |